Patent: 9,988,462
✉ Email this page to a colleague
Summary for Patent: 9,988,462
Title: | Material and methods for treating or preventing HER-3 associated diseases |
Abstract: | Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example. |
Inventor(s): | Hettmann; Thore (Munich, DE), Freeman; Daniel J. (Newbury Park, CA), Radinsky; Robert (Thousand Oaks, CA), Rothe; Mike (Krailling, DE) |
Assignee: | |
Application Number: | 15/000,005 |
Patent Claims: | see list of patent claims |
Details for Patent 9,988,462
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2025-12-30 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2025-12-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |